Zealand Pharma

Clinical trials sponsored by Zealand Pharma, explained in plain language.

Zealand Pharma ZEAL NASDAQ

A biopharmaceutical company focused on peptide-based medicines for metabolic and gastrointestinal diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Can a new drug called ZP9830 calm psoriasis Flare-Ups? Results expected Apr 2027 (estimated)
Liver function may affect how Weight-Loss drug petrelintide works Results expected Apr 2027 (estimated)
Can a new injectable drug safely tackle weight? an early trial seeks answers Results expected Sep 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 5 Not yet finished but already full! 1 Completed 7

New drug shows promise for managing short bowel syndrome Long-Term

Disease control Ongoing

This study looks at the long-term safety and effectiveness of a drug called glepaglutide in adults with short bowel syndrome (SBS), a condition where the body can't absorb enough nutrients from food. Participants who were already in earlier trials can continue treatment for up to…

Phase 3 • Sponsor: Zealand Pharma • Aim: Disease control

Last updated Aug 01, 2026 00:00 UTC

Zealand Pharma

Upcoming readouts

New drug shows promise for managing short bowel syndrome Long-Term